Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (57)	7/9/1999 10:38:00 AM
From: Tupulak	Read Replies (1) \| Respond to of 164

Here is a brand new one.. Canadian Company Press Release SYB 1999-07-09 (provided courtesy of Canadian Corporate News.) register to receive future releases by email from CCN SYNSORB Biotech Inc. Appoints New Director CALGARY, ALBERTA--SYNSORB Biotech Inc. ("SYNSORB") (TSE: SYB; Nasdaq: SYBB) today announced the appointment of Richard L. Casey, formerly of Scios Inc., to the Company's Board of Directors. Mr. Casey has over 25 years of experience in the pharmaceutical industry, and most recently served as Chairman, President and CEO for Scios Inc., a biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of novel human therapeutics. A New Drug Application for Scios' lead product for congestive heart failure is currently being reviewed by the USFDA. Prior to joining Scios in 1987, Mr. Casey served as the President of Alza Pharmaceuticals Division, a company that develops and markets specialized drug delivery products. From 1976 to 1985, Mr. Casey held various positions within Syntex, including Director of Market Research, Vice President of Sales, and General Manager of the Medical Diagnostics Division. Prior thereto, he held various sales and marketing roles with Eli Lilly. Mr. Casey retired from Scios in 1998 and is currently serving on the Board of Directors of Guilford Pharmaceuticals, a biotechnology company focussed on diseases of the Central Nervous System. "Mr. Casey's experience in bringing products through the development phase and establishing corporate partnerships are critical to SYNSORB," said Dr. Brad Thompson, Chairman of the Board in announcing the appointment. "We are extremely pleased to welcome Mr. Casey to SYNSORB's Board of Directors." SYNSORB is dedicated to accelerated drug development from the acquisition of promising compounds emerging from basic research through clinical development, and ultimately to providing channels to market for new discoveries. Headquartered in Calgary, SYNSORB currently has two products in late stage clinical development, SYNSORB Pk(R) for the prevention of HUS and the treatment of verotoxigenic E. coli (VTEC) infections (including O157:H7), and SYNSORB Cd(R) designed to treat recurrent antibiotic-associated diarrhea (CDAD). SYNSORB has additional compounds in pre-clinical development, including REOSYN, a potential cancer treatment being developed within its subsidiary company, Oncolytics Biotech Inc., and novel antibiotics, with inflammation and anti-virals targeted in the Company's research and development program. Shares of SYNSORB Biotech Inc. trade on the Toronto Stock Exchange in Canada (symbol "SYB") and on NASDAQ in the United States (ticker "SYBB"). This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. -30- FOR FURTHER INFORMATION PLEASE CONTACT: SYNSORB Biotech Inc. Dr. David Cox President & CEO (403) 283-5900 (403) 283-5907 (FAX) synsorb.com or The Equicom Group Jason Hogan Investor Relations (416) 815-0700 ex 222 (416) 815-0080 (FAX) jhogan@equicomgroup.com